2014 Generics Sales: $1.6 billion -1%
Worldwide Market Share: 2.2%
Stada Arzneimittel reeled in $1.6 billion in 2014 generics revenue, virtually identical to its 2013 revenue, but not good enough to keep the No. 11 spot. EvaluatePharma clocks this as a 1% decrease in sales, dropping the German pharma to No. 13.
Generics are very important to the German drugmaker, accounting for 59% of Stada's group sales, and its top 5 generic products tallying up 9.8% of those generics sales. Of those 5, generic Lipitor sales grew 13%, omeprazole sales 10% and diclofenac sales 2%. However, the other two in the top 5 declined, most notably the liver medicine phospholipide, which saw a 27% slide.
It wasn't an easy year for the German pharma, which had to dampen its earnings forecast in early 2014, as unrest in Russia and Ukraine started taking a toll. But CEO Hartmut Retzlaff said the company hadn't given up on its expansion plans in Eastern Europe and coyly alluded to some M&A deals that might be in its future. He didn't disclose any targets but called the talks "promising."
Stada also got caught up in the problems of Indian clinical trial company GVK Biosciences. The European Medicines Agency suspended sales of 80 drugs made by 16 drugmakers, Stada among them, after inspectors found that a number of electrocardiograms were falsified by employees at GVK, a claim the company denied.
And while 2014 was a tough year for Stada, Retzlaff did a little extra to ease the company's financial woes. In November 2014, he agreed to a 40% pension cut of about €16 million to about €24 million, a far cry from the retirement packages that pharma bosses can take home in the U.S.
-- Amirah Al Idrus (email | Twitter)
Stada, Dr. Reddy's and others dodge German drug suspensions with appeals
Mylan, Stada, Dr. Reddy's drugs suspended after contractor's trial failures
Stada CEO 'happy' to take 40% pension cut. Sound foreign, U.S. pharma chiefs?
Persevering in Eastern Europe despite unrest, Stada eyes more deals